Virginia Commonwealth University Medical Center

Richmond, VA

Sorting 5 by

Accepting patients

ELEMENT-MDS

Phase 3 Clinical Trial Comparing Luspatercept VS Epoetin Alfa in Patients with Very Low – Intermediate Risk MDS Who Are Not Transfusion Dependent
  • Erythroid Maturation Agent (EMA)
  • Erythropoiesis-Stimulating Agent (ESA)
  • Red Blood Cell Stimulant
  • Phase 3

Accepting patients

ACCESS

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)
  • Allogeneic Stem Cell Transplant
  • Pre-Transplant
  • Phase 2

Accepting patients

LYT-200

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
  • Monoclonal Antibody
  • Galectin-9 Protein
  • Phase 1
  • Has results

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

Cord Blood Units for Neutrophil Recovery

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
  • Cord Blood
  • Observational Trial